Vyvgart Iv MG denied as not FDA-approved for this use by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for vyvgart iv mg are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare May Issue a "Not FDA-Approved" Denial for Vyvgart (efgartigimod alfa) IV

Vyvgart (efgartigimod alfa) received FDA approval for generalized myasthenia gravis (gMG) in adults who are anti-AChR antibody positive. UnitedHealthcare may issue a "not FDA-approved" denial when your claim is coded for an indication or patient population that falls outside the FDA-approved label — for example, an off-label use such as a different neuromuscular condition, a pediatric patient, or a formulation/route not matching the approved product.

## Why This Denial Is Appealable

If your physician prescribed Vyvgart IV for the exact FDA-approved indication, this denial may rest on a coding error, missing diagnosis documentation, or an internal policy misread of the label. Even where a use is technically off-label, federal law and many state laws protect patients' rights to appeal when substantial clinical evidence supports the treatment.

## Your Federal Appeal Rights

• Internal appeal: You have the right to a full internal appeal under ACA §2719 and ERISA §503's full-and-fair review standard. Submit within your plan's stated deadline (commonly 180 days from the denial date).
• External review: If the internal appeal is denied, you may escalate to an Independent Review Organization (IRO) under ACA §2719. You generally have approximately four months from the final internal denial to request external review.
• Expedited review: If your condition is urgent or your health is at serious risk, request expedited external review — decisions are typically required within 72 hours.

## Documentation to Gather

1. Diagnosis confirmation: Records confirming the FDA-approved diagnosis (e.g., gMG), including antibody testing results and neurologist notes. 2. Prior treatment history: Dates, regimens, and outcomes of all prior therapies, demonstrating the treatment pathway that led to this prescription. 3. Clinical severity: Objective severity assessments documented in the medical chart. 4. Prescriber letter: A detailed medical-necessity letter from the prescribing neurologist explaining how the prescribed use aligns with the FDA-approved label and current clinical guidelines from the relevant professional society.

## Criteria-Mapping Structure for Your Appeal

Pull the FDA-approved prescribing information directly from the manufacturer or DailyMed and compare each indication requirement against your chart. Then obtain UnitedHealthcare's published Coverage Determination Guideline for efgartigimod and map every listed criterion to a specific chart document. Present a side-by-side table: criterion → supporting chart evidence → page/date of record. Addressing each criterion explicitly gives the reviewer no grounds to deny on a technicality.

## Next Step

Request the specific denial reason code and the internal guideline used, which UHC is required to provide. This will confirm exactly which criterion triggered the denial and allow your physician to address it directly.